.png){kind=icon}
Return
Abrocitinib: First Approval
.png){kind=icon}
OA
AI
DOI：10.1007/s40265-021-01638-3.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Abrocitinib (Cibinqo(R)) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD). In September 2021, abrocitinib was approved in the UK and Japan for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older who are candidates for systemic therapy. Abrocitinib has also received a positive CHMP opinion in the EU for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. Regulatory applications for the drug have also been submitted for review to several other countries, including the USA and Australia. This article summarizes the milestones in the development of abrocitinib leading to this first approval for the treatment of moderate-to-severe AD.
Keywords:
JAK1 INHIBITOR
DUPILUMAB
PF-04965842
PLACEBO
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
14.4
Papers:
8.4K
Citations:
2.3W
Organization
No organization information available
Cited Papers
Pancreaticoduodenectomy for Peri-Ampullary Neoplasia Leads to Specific Micronutrient Deficiencies
PREAI
ShareSaveEfficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial.png)
JAMA DERMATOLOGYOAAI
JAMA DERMATOLOGYIF11
OAAIShareSavePatient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With AbrocitinibDERMATITIS
OAAI
DERMATITISIF3.2
OAAIShareSaveShareSave
View more